Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹904 Cr
verified against source
Revenue YoY
-5%
reported change
EBITDA
₹241 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
JB Chemicals reported a weak Q4 FY26 with revenue of ₹904 crore, down 5% YoY, as the quarter was an operational reset post Torrent Pharma's acquisition. Adjusted EBITDA margin improved to 27% (up 200 bps YoY) driven by discontinuation of low-margin trade generics and distribution optimization. India branded business grew 8% (vs reported 2%), while international formulations declined due to container shipment disruptions. Management expects gradual normalization: India branded growth to return to low teens in a couple of quarters, international single-digit growth from Q2. CDMO business faces execution delays but has strong customer pipeline. Merger with Torrent expected to complete in 1-2 months. Key risk: West Asia shipping disruptions may persist, delaying international recovery.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects India branded business to recover to double-digit/low-teens growth within 2 quarters.
- International formulations expected to resume single-digit growth from Q2 FY27, assuming West Asia crisis eases.
- Merger with Torrent Pharma expected to be effective within 1-2 months, with hearing in second week of June.
- CDMO business expected to grow on a 12-month basis, driven by new projects and contracts, but execution remains key.
Risks flagged
- Container shipment constraints to West Asia and Asia impacted international business; Q1 remains uncertain.
- CDMO business faces delays in product development and delivery of new contracts, which could hinder growth.
- Discontinuation of trade generics (7-8% of India sales) will continue to suppress reported India growth for next 3 quarters.
- Higher attrition in JB's field force and potential rationalization may disrupt sales momentum.
Key quotes
- Q4 was a period of operational reset which temporarily impacted performance. However, we expect normalization beginning in Q1 and continuing going forward.
- The trade generics business is not really a focus for us from here. We're looking at only growing the branded business more.
- The good part is the customers are there. So JBI has all the top five customers and it has new contracts on hand. So the challenge is just the execution part.
Research modules